Clinical Scorecard: Investigating the Role of KMT2C Alterations in Gastrointestinal Cancers: Disruption of Enhancer Networks, Lineage Flexibility, and Implications for Clinical Practice
At a Glance
Category
Detail
Condition
Key Mechanisms
Alterations in KMT2C lead to destabilization of enhancer and super-enhancer networks, affecting transcriptional programs.
Target Population
Care Setting
Key Highlights
KMT2C alterations are predominantly truncating loss-of-function variants and splice-disrupting events.
KMT2C deficiency leads to large-scale transcriptional rewiring and activation of stress-adaptive programs.
KMT2C dysfunction is linked to tumor mutational burden (TMB) and microsatellite instability (MSI).
KMT2C-associated DNA repair deficiencies provide a basis for synthetic-lethal strategies.
Guideline-Based Recommendations
Diagnosis
Evaluate KMT2C alterations in gastrointestinal cancers through genomic sequencing.
Management
Consider treatment options for patients with KMT2C-associated DNA repair deficiencies.
Monitoring & Follow-up
Implement tissue-based profiling and liquid biopsy monitoring for KMT2C alterations.
Risks
Monitor for increased genomic instability in patients with KMT2C alterations.
Patient & Prescribing Data
Patients with gastrointestinal cancers exhibiting KMT2C alterations.
Clinical Best Practices
Adopt a closed-loop validation strategy for assessing KMT2C-related therapeutic approaches.
